EA015339B1 - Связывающие fgf2 пептиды и их применение - Google Patents

Связывающие fgf2 пептиды и их применение Download PDF

Info

Publication number
EA015339B1
EA015339B1 EA200870188A EA200870188A EA015339B1 EA 015339 B1 EA015339 B1 EA 015339B1 EA 200870188 A EA200870188 A EA 200870188A EA 200870188 A EA200870188 A EA 200870188A EA 015339 B1 EA015339 B1 EA 015339B1
Authority
EA
Eurasian Patent Office
Prior art keywords
ptx3
amino acid
peptide
cells
ece2
Prior art date
Application number
EA200870188A
Other languages
English (en)
Russian (ru)
Other versions
EA200870188A1 (ru
Inventor
Марко Преста
Маура Камоцци
Марко Руснати
Маурицио Коломбо
Доменико Мастроянни
Original Assignee
Текноджен С.П.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Текноджен С.П.А. filed Critical Текноджен С.П.А.
Publication of EA200870188A1 publication Critical patent/EA200870188A1/ru
Publication of EA015339B1 publication Critical patent/EA015339B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Dermatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
EA200870188A 2006-01-24 2007-01-23 Связывающие fgf2 пептиды и их применение EA015339B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06001457 2006-01-24
PCT/EP2007/000538 WO2007085412A1 (en) 2006-01-24 2007-01-23 Fgf2-binding peptides and uses thereof

Publications (2)

Publication Number Publication Date
EA200870188A1 EA200870188A1 (ru) 2009-02-27
EA015339B1 true EA015339B1 (ru) 2011-06-30

Family

ID=37421191

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200870188A EA015339B1 (ru) 2006-01-24 2007-01-23 Связывающие fgf2 пептиды и их применение

Country Status (19)

Country Link
US (1) US8076300B2 (enExample)
EP (1) EP1973944B1 (enExample)
JP (1) JP5427415B2 (enExample)
KR (1) KR101467453B1 (enExample)
CN (1) CN101384622B (enExample)
AU (1) AU2007209581B2 (enExample)
BR (1) BRPI0707239A8 (enExample)
CA (1) CA2637295C (enExample)
DK (1) DK1973944T3 (enExample)
EA (1) EA015339B1 (enExample)
ES (1) ES2575517T3 (enExample)
HR (1) HRP20160600T1 (enExample)
HU (1) HUE029212T2 (enExample)
IL (1) IL192800A (enExample)
MX (1) MX2008009289A (enExample)
PL (1) PL1973944T3 (enExample)
PT (1) PT1973944T (enExample)
SI (1) SI1973944T1 (enExample)
WO (1) WO2007085412A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018204928A1 (en) * 2017-05-05 2018-11-08 Board Of Regents, The University Of Texas System Fgl2 monoclonal antibodies and their use in treating malignant tumors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002038169A1 (en) * 2000-11-08 2002-05-16 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of the long pentraxin ptx3 for the treatment of diseases caused by an altered activation of the growth factor fgf-2

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1298487B1 (it) * 1997-12-19 2000-01-10 Sigma Tau Ind Farmaceuti Composizioni farmaceutiche comprendenti pentraxina lunga ptx3 per la terapia di patologie di tipo infettivo, infiammatorio o tumorale,
ITRM20020109A1 (it) * 2002-02-28 2003-08-28 Sigma Tau Ind Farmaceuti Derivati funzionali della pentraxina lunga ptx3 per preparare un vaccino autologo per la cura dei tumori.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002038169A1 (en) * 2000-11-08 2002-05-16 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Use of the long pentraxin ptx3 for the treatment of diseases caused by an altered activation of the growth factor fgf-2

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CAMOZZI MAURA ET AL.: "Identification of an antiangiogenic FGF2-binding site in the N terminus of the soluble pattern recognition receptor PTX3". THE JOURNAL OF BIOLOGICAL CHEMISTRY 11 AUG 2006, vol. 281, no. 32, 11 August 2006 (2006-08-11), pages 22605-22613, XP002408922 ISSN; 0021-9258 *
CAMOZZI MAURA ET AL.: "Pentraxin 3 inhibits fibroblast growth factor 2-dependent activation of smooth muscle cells in vitro and neointima formation in vivo". ARTERIOSCLEROSIS, THROMBOSIS, AND VASCULAR BIOLOGY. SEP 2005, vol. 25, no. 9, September 2005 (2005-09), pages 1837-1842, XP002408921 ISSN: 1524-4636, page 1840, right-hand column, paragraph 2 - page 1841, right-hand column, paragraph 2 *
PEROLLET S. ET AL.: "Platelet factor 4 modulates fibroblast growth factor 2 (FGF-2) activity and inhibits FGF-2 dimerization". BLOOD 1 MAY 1998, vol. 91, no. 9, 1 May 1998 (1998-05-01), pages 3289-3299, XP002439184 ISSN: 0006-4971, page 3295, right-hand column, paragraph 3 - page 3297, right-hand column, paragraph 2 *
PRESTA MARCO ET AL.: "Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis". CYTOKINE & GROWTH FACTOR REVIEWS APR 2005, vol. 16, no. 2, April 2005 (2005-04), pages 159-178, XP002439183 ISSN: 1359-6101 table 1 *
RUSNATI MARCO ET AL.: "Selective recognition of fibroblast growth factor-2 by the long pentraxin PTX3 inhibits angiogenesis". BLOOD. 1 JUL 2004, vol. 104, no. 1, 1 July 2004 (2004-07-01), pages 92-99, XP002408920 ISSN: 0006-4971 the whole document *

Also Published As

Publication number Publication date
MX2008009289A (es) 2008-10-17
HRP20160600T1 (hr) 2016-07-01
KR101467453B1 (ko) 2014-12-01
CA2637295A1 (en) 2007-08-02
AU2007209581B2 (en) 2013-03-28
CN101384622B (zh) 2013-03-27
DK1973944T3 (en) 2016-06-27
SI1973944T1 (sl) 2016-07-29
BRPI0707239A8 (pt) 2018-01-30
ES2575517T3 (es) 2016-06-29
KR20080096794A (ko) 2008-11-03
IL192800A0 (en) 2009-02-11
WO2007085412B1 (en) 2007-10-11
JP2009523457A (ja) 2009-06-25
IL192800A (en) 2015-04-30
BRPI0707239A2 (pt) 2011-04-26
HUE029212T2 (en) 2017-02-28
CN101384622A (zh) 2009-03-11
EP1973944A1 (en) 2008-10-01
PL1973944T3 (pl) 2016-09-30
PT1973944T (pt) 2016-07-07
EA200870188A1 (ru) 2009-02-27
US20090215689A1 (en) 2009-08-27
EP1973944B1 (en) 2016-05-11
WO2007085412A1 (en) 2007-08-02
CA2637295C (en) 2017-06-13
AU2007209581A1 (en) 2007-08-02
US8076300B2 (en) 2011-12-13
JP5427415B2 (ja) 2014-02-26

Similar Documents

Publication Publication Date Title
US5607918A (en) Vascular endothelial growth factor-B and DNA coding therefor
US5928939A (en) Vascular endothelial growth factor-b and dna coding therefor
JP5490343B2 (ja) Ｊｎｋシグナル導入経路の細胞透過性ペプチドインヒビター
US20100215655A1 (en) Angiogenesis-inhibiting chimeric proteins and the use
KR20070092706A (ko) 조혈을 촉진하는 분자
US9611306B2 (en) TGFB type II-type III receptor fusions
EP1495050A1 (en) Novel antagonists of mcp proteins
CN103038351A (zh) 玻连蛋白:角质化细胞生长因子嵌合体
EA015339B1 (ru) Связывающие fgf2 пептиды и их применение
JP2008013436A (ja) 血管形成促進剤
US20170166624A1 (en) TGFß TYPE II-TYPE III RECEPTOR FUSIONS
EP1901761A2 (en) Thrombospondin-1 derived peptides and treatment methods
JP5142246B2 (ja) ラミニン６ｂ（ラミニン３ｂ１１）蛋白質
WO2008077938A1 (en) Modulators of talin/integrin association and use thereof
HK1120742A (en) Thrombospondin-1 derived peptides and treatment methods

Legal Events

Date Code Title Description
PC4A Registration of transfer of a eurasian patent by assignment
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU